We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics
Read MoreHide Full Article
Laboratory Corporation of Americas Holdings (LH - Free Report) , popularly known as LabCorp, recently collaborated with Unilabs — a leading European provider of clinical laboratory testing and medical diagnostic imaging services. The terms of the deal have been kept under wraps.
Per LabCorp, the companies will start with commercialization of assays which have been designed and tested analytically and clinically by LabCorp and its Covance drug development business. Through this collaboration, LabCorp and Unilabs aim at increasing access to commercialization channels for companion diagnostics in North America and Europe.
The companies also intend to drive the uptake of companion diagnostics by widening the laboratories network accessed by biopharmaceutical companies. Starting with oncology, particularly immuno-oncology, LabCorp and Unilabs will work toward simplifying the technical, regulatory and clinical complexities related with critical assays.
Collaborations on Track
LabCorp has strengthened its foothold in the diagnostics space through organic and inorganic means and plans to collaborate with leading companies and academic institutions to offer a wider portfolio of tests.
Among the recent alliances, the company has announced the extension of its existing partnership agreement with Aetna . Of late, the company has been dominating the headlines on its announcement of expanding partnership with UnitedHealthcare, a business of UnitedHealth Group (UNH - Free Report) to continue to serve as UnitedHealthcare’s exclusive national laboratory provider till Jan 1, 2019.
Further, the company’s comprehensive laboratory collaboration with Appalachian Regional Healthcare, an 11-hospital health system in Kentucky and West Virginia, is worth a mention. This apart, the company has expanded its relationship with Mount Sinai to consolidate all of the latter’s reference work and streamline its inpatient labs.
Also, LabCorp’s Covance business recently entered a strategic technology agreement with GlaxoSmithKline plc (GSK - Free Report) . Under the terms of the agreement, GlaxoSmithKline will use Covance’s Xcellerate Monitoring, Xcellerate Insights and Xcellerate Clinical Data Hub solutions as a software-as-a-service model.
Other recent partnerships include the one with Thermo Fisher (TMO - Free Report) , which enabled the launch of Thermo Fisher Oncomine Dx target panel for non-small cell lung cancer patients. Also, LabCorp works on developing and operating patient service centers within select Walgreens stores through its drug retailer Walgreens (WBA - Free Report) .
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
Image: Bigstock
LabCorp, Unilabs Tie Up to Expand in Companion Diagnostics
Laboratory Corporation of Americas Holdings (LH - Free Report) , popularly known as LabCorp, recently collaborated with Unilabs — a leading European provider of clinical laboratory testing and medical diagnostic imaging services. The terms of the deal have been kept under wraps.
Per LabCorp, the companies will start with commercialization of assays which have been designed and tested analytically and clinically by LabCorp and its Covance drug development business. Through this collaboration, LabCorp and Unilabs aim at increasing access to commercialization channels for companion diagnostics in North America and Europe.
The companies also intend to drive the uptake of companion diagnostics by widening the laboratories network accessed by biopharmaceutical companies. Starting with oncology, particularly immuno-oncology, LabCorp and Unilabs will work toward simplifying the technical, regulatory and clinical complexities related with critical assays.
Collaborations on Track
LabCorp has strengthened its foothold in the diagnostics space through organic and inorganic means and plans to collaborate with leading companies and academic institutions to offer a wider portfolio of tests.
Among the recent alliances, the company has announced the extension of its existing partnership agreement with Aetna . Of late, the company has been dominating the headlines on its announcement of expanding partnership with UnitedHealthcare, a business of UnitedHealth Group (UNH - Free Report) to continue to serve as UnitedHealthcare’s exclusive national laboratory provider till Jan 1, 2019.
Further, the company’s comprehensive laboratory collaboration with Appalachian Regional Healthcare, an 11-hospital health system in Kentucky and West Virginia, is worth a mention. This apart, the company has expanded its relationship with Mount Sinai to consolidate all of the latter’s reference work and streamline its inpatient labs.
Also, LabCorp’s Covance business recently entered a strategic technology agreement with GlaxoSmithKline plc (GSK - Free Report) . Under the terms of the agreement, GlaxoSmithKline will use Covance’s Xcellerate Monitoring, Xcellerate Insights and Xcellerate Clinical Data Hub solutions as a software-as-a-service model.
Other recent partnerships include the one with Thermo Fisher (TMO - Free Report) , which enabled the launch of Thermo Fisher Oncomine Dx target panel for non-small cell lung cancer patients. Also, LabCorp works on developing and operating patient service centers within select Walgreens stores through its drug retailer Walgreens (WBA - Free Report) .
Share Price Performance
Over the past six months, shares of this Zacks Rank #3 (Hold) company have outperformed its industry. The stock has gained 17.7% compared with the industry’s 3.4% gain. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
The Hottest Tech Mega-Trend of All
Last year, it generated $8 billion in global revenues. By 2020, it's predicted to blast through the roof to $47 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.
See Zacks' 3 Best Stocks to Play This Trend >>